Iron overload in Hepc1−/− mice is not impairing glucose homeostasis  by Ramey, G. et al.
FEBS Letters 581 (2007) 1053–1057Iron overload in Hepc1/ mice is not impairing glucose homeostasis
G. Ramey1, A. Faye1, B. Durel, B. Viollet, S. Vaulont*
Institut Cochin, De´partement Endocrinologie Me´tabolisme et Cancer, Paris, F-75014, France
Inserm, U567, Paris, F-75014, France
CNRS, UMR 8104, Paris, F-75014, France
Universite´ Paris 5, Faculte´ de Me´decine Rene´ Descartes, UM 3, Paris, F-75014, France
Received 15 December 2006; revised 25 January 2007; accepted 4 February 2007
Available online 12 February 2007
Edited by Robert BaroukiAbstract Diabetes Mellitus is found with increasing frequency
in iron overload patients with hemochromatosis. In these condi-
tions, the pancreas shows predominant iron overload in acini
but also islet b-cells. We assess glucose homeostasis status in
iron-overloaded hepcidin-deﬁcient mice. These mice presented
with heavy pancreatic iron deposits but only in the acini. The
b-cell function was found unaﬀected with a normal production
and secretion of insulin. The mutant mice were not diabetic,
responded as the control group to glucose and insulin challenges,
with no alteration of insulin signalling in the muscle and the liver.
These results indicate that, b-cells iron deposits-induced
decreased insulin secretory capacity might be of primary impor-
tance to trigger diabetes in hemochromatosic patients.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In mammals, iron homeostasis is complex and depends on
the regulated absorption of dietary iron by mature enterocytes
of the duodenum and iron recycling by macrophages [1]. These
two fundamental processes are deregulated in hereditary
hemochromatosis (HH), leading, over time, to transferrin sat-
uration and iron deposition in parenchymal cells [2]. HH is a
highly prevalent iron overload disorder that is, unless recog-
nized and treated, fatal. As the disease progresses, patients
develop iron-induced tissue damage resulting in serious ill-
nesses including cirrhosis, hepatomas, cardiomyopathy, arthri-
tis, endocrinopaties and diabetes. HH is genetically
heterogeneous depending on distinct clinical and genetic enti-
ties. Classical hemochromatosis is associated with the histori-
cal and most prevalent form of HH, almost always caused
by mutations in HFE and rarely in transferrin receptor 2
(TfR2) (reviewed in [3]). Juvenile hemochromatosis (JH) is a
rare form of the disease characterized by the early and severe
onset of symptoms, in particular cardiac and endocrine*Corresponding author. Fax: +33 1 44412421.
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cloned hemojuvelin (HJV) gene (reviewed in [3]). For a very
small subset of patients, mutations have been identiﬁed in hep-
cidin (HAMP), which encodes a small circulating 25-amino-
acid cysteine-rich peptide that constitutes the master regulator
of iron homeostasis (reviewed in [3]). The circulating peptide
acts to limit gastrointestinal iron absorption and serum iron
by inhibiting dietary intestinal iron absorption and iron recy-
cling by the macrophages [4]. To limit iron egress, hepcidin
binds to ferroportin, the transmembrane iron transporter
necessary for iron transfer out of intestinal epithelial cells
and macrophages [5], thereby inducing its internalization and
subsequent degradation [6–8]. Most of the iron overload syn-
dromes known to date (primary hemochromatosis and second-
ary iron overloads) imply a reduction of hepcidin secretion. In
contrast, hypersecretion of hepcidin seems to play a determin-
ing role in anemia of chronic disease [9].
Diabetes is part of the triad originally used to deﬁne fully pe-
netrant HH. However, so far, the pathophysiology of the dia-
betes associated with HH is poorly understood and the actual
prevalence of diabetes in HH is still subjected to debate [10]. It
is generally admitted that two mechanisms contribute to the
development of hyperglycemia and diabetes in hemochromato-
sic patients; liver iron overload, leading to insulinoresistance,
and pancreatic b-cell iron accumulation, resulting in cell dam-
age and diminished insulin secretion [11–13]. Further support
for a toxic role of iron in the b-cell has been reported in pa-
tients with thalassemia [10] and in rats subjected to experimen-
tal iron overload [14,15]. Since studies of the mechanisms of
hemochromatosis-associated diabetes have been limited in
mouse models, we sought to analyze glucose metabolism in
our recently generated Hepc1 knockout mice. These mice pre-
sented an iron overload phenotype similar to that observed in
HH, with increased iron deposition in the liver and the pan-
creas, representing therefore a good model to assess to what
extend iron can induce impairment in glucose homeostasis in
mice.2. Materials and methods
2.1. Animals
Hepcidin knockout mice were previously described [16]. All the stud-
ies were carried on F1 hybrids on a mixed C57BL/6 X 129 background.
Animals were cared for in accordance with the ‘‘European convention
for the protection of laboratory animals’’. Animals were maintained in
a temperature- and light-controlled environment and were given free
access to tap water and food (standard laboratory mouse chow,
AO3, iron content 280 mg/kg, UAR, France).blished by Elsevier B.V. All rights reserved.
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For histology, tissues were ﬁxed in 4% formaldehyde, and
embedded in paraﬃn. Sections were immersed in Perls’ solution (1:1,
2% HCl and 2% potassium ferrocyanide) to visualize ferric (non-heme)
iron and counterstained with nuclear fast red using standard proce-
dures. Insulin immunochemistry was performed as previously de-
scribed [17].
2.3. Blood parameters
Blood was withdrawn from the tail using EDTA-aprotinin as the
anticoagulant. Blood glucose levels were assessed using a glucometer
(Glucotrend II, Roche Laboratories, France). Plasma insulin concen-
trations were assessed using a rat insulin ELISA kit with a mouse insu-
lin standard (Crystal Chem. Inc., Chicago, IL, USA).
2.4. Glucose and Insulin Tolerance Tests
OGTT was performed as previously described on mice fasted over-
night for 12 h [18]. Blood glucose levels were determined at 0, 20, 40,
60, and 80 min after an oral bolus of glucose (3 g/kg of body
weight). Blood was also collected at t = 0 and after 20 min for
determination of plasma insulin concentration. For insulin tolerance
test (ITT), animals fasted for 4 h (from 10:00 AM to 14:00 PM) were
injected intraperitoneally with 0.5 U/kg of insulin and glucose
levels were measured at 0, 15, 30, 60 and 90 min post-injection
[18].
2.5. Insulin signalling
For insulin signalling experiments, following an overnight fast, mice
were anesthetized with a ketamine/xylazine mix and injected with 5 U/
kg of regular human insulin (Actrapid Penﬁll; NovoNordisk Inc.) via
the portal vein. Three and ﬁve minutes after the injection of insulin bo-
lus, livers and muscles were removed, respectively, and frozen in liquid
nitrogen. Immunoblot analysis of the insulin signalling was performed
as described on AKT phosphorylation [18].Fig. 1. Pancreas iron and insulin content in hepc1 knockout mice. Typical pan
mice aged of 8 months. For Perls’ staining (A), non-heme iron stains blue. F
show the islets.3. Results
3.1. Hepc1/ animals accumulated iron in the exocrine
pancreas and presented normal plasma and pancreatic levels
of insulin
We previously reported accumulation of iron in the pancreas
of Hepc1/ mice [16]. Further examination of pancreatic iron
accumulation by staining histological sections for iron showed
that iron accumulated predominantly in the exocrine pancreas,
with sparing of the islets (Fig. 1A). This massive iron accumu-
lation was not associated with ﬁbrosis nor with pancreatitis as
judged by the absence of collagen deposition (trichrome stain-
ing, not shown) and normal levels of pancreatic enzymes
(lipase and amylase activities measured in the plasma of
Hepc1/ mice, not shown). The function of the b-cells in
the Hepc1/ mice was next analyzed. The insulin content in
the pancreas of Hepc1/ mice was determined by immuno-
chemistry and showed no diﬀerence with the controls
(Fig. 1B). Furthermore, plasma insulin levels in fed animals
was not aﬀected in the mutant mice (0.73 ± 0.44 ng/ml in
Hepc1/ mice, n = 7, vs 0.71 ± 0.33 in control mice, n = 9).
These results suggest that the iron overload of the exocrine
pancreas is not aﬀecting the production and secretion of insu-
lin in Hepc1/ mice.
3.2. Unaltered glucose homeostasis in Hepc1/ animals
To further explore the eﬀects of iron overload on insulin sen-
sitivity and glucose eﬀectiveness, oral glucose and insulin toler-
ance tests were performed. As shown in Fig. 2A, Hepc1/creas sections (original magniﬁcation 20·) fromHepc1+/+ andHepc1/
or insulin immunohistochemistry (B), insulin stains brown. The arrows
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dency, although not statistically signiﬁcant, to an increased
glucose tolerance. Importantly, there was no signiﬁcant diﬀer-
ence in blood glucose levels at the fasted state between the
mutant and control mice indicating the absence of hyperglyce-
mia in mutant mice. Insulin levels were comparable inHepc1/
and control mice in the fasting state as well as 20 min after the
glucose challenge (Fig. 2B). Finally, insulin tolerance test re-
vealed no signiﬁcant diﬀerences in insulin sensitivity between
the Hepc1/ and the control mice (Fig. 2C). However,Fig. 2. Glucose and insulin tolerance analyses in hepc1 knockout mice. (A)
(Hepc1+/+ and Hepc1+/ mice) and Hepc1/ mice aged of 12 months (co
determined at the indicated times. (B) Plasma insulin levels were determined b
(0.5 U/kg body weight) was administered ip, and blood glucose levels were
n = 8). Data are the mean ± S.E.M. Statistical analysis was performed usingalthough not signiﬁcant, the tendency of impaired reduction
in blood glucose concentration after intraperitoneal adminis-
tration of insulin in Hepc1/ mice prompted us to further
analyze the insulin resistance state of the mutant mice by
studying the activation of the insulin signalling pathway. To
that purpose, AKT phosphorylation was evaluated after
insulin injection in liver and muscle of overnight-fasted control
and mutant mice. As shown in Fig. 3, the stimulation by insu-
lin of Akt phosphorylation was similar in livers and muscles of
control and Hepc1/ mice. Collectively, these results suggestA bolus of glucose (3 g/kg body weight) was administered in control
ntrol, n = 8 and Hepc1/ mice, n = 8). Tail vein glucose levels were
efore and 20 min after glucose injection in the same cohort. (C) Insulin
determined at the indicated times (control, n = 8 and Hepc1/ mice,
Student’s t-test (unpaired, two tailed).
Fig. 3. Insulin signalling in hepc1 knockout mice. Analysis of insulin-induced Akt phosphorylation by Western blot. Following an overnight fast,
mice were either sacriﬁced () or injected for with 5 U/kg of insulin via the portal vein (+insulin). Three and ﬁve min after insulin injection, liver and
muscle were, respectively, collected and frozen. Proteins (50 lg) from liver and skeletal muscle from control and Hepc1/ mice were resolved by
SDS–polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, and probed with rabbit polyclonal total and phospho-Akt
antibodies. Molecular weight markers (kDa) are indicated on the left.
1056 G. Ramey et al. / FEBS Letters 581 (2007) 1053–1057that whole body insulin sensitivity is preserved in Hepc1/
mice and that the liver iron overload of mutant mice is not
inducing an hepatic insulin resistance.4. Discussion
In humans, diﬀerent studies support a b-cell defect in HH
and a pathogenic role of iron in the b-cell [12,13,19]. Impor-
tantly, it was reported that impaired insulin secretory
responses may be reversed to some extend by therapeutic phle-
botomies [12]. In the recent report of McClain et al. [13], the
authors demonstrated that the high prevalence of abnormal
glucose homeostasis primarily involved insulin secretory de-
fects in individual with HH. The authors reported that hemo-
chromatosic patients with impaired glucose tolerance were not
insulin-resistant but presented with a decrease in insulin
response to glucose, while hemochromatosic patients with dia-
betes exhibited further declines in insulin response to glucose,
insulin-resistance or both [13].
The resistance of mice to iron-induced diabetes was recently
exempliﬁed in the Hjv knockout mice which, despite an heavy
iron overload, were not described as being diabetic [20]. A
complete study of glucose metabolism was also reported in
Hfe/mice i.e. the mouse model of classical hemochromatosis
[21]. The authors found that the Hfe/ mice were not glucose
intolerant nor insulin-resistant. However, a 1.7 fold increase of
iron in isolated pancreatic islets was described resulting in
decreased insulin secretion secondary to b-cell apoptosis, loss
of b-cell mass and desensitization of glucose-induced insulin
secretion in the mutant Hfe/ mice. In Hepc1/ mice, we
were unable to detect any increase of b-cells apoptosis with
activated caspase 3 (not shown). The reason of the iron loading
resistance of the Hepc1/ b-cell is not clear and deserves fur-
ther examination. However, even with the b-cell dysfunction in
the Hfe/ mice, these mice are able to compensate and do not
develop diabetes [21].
The resistance of iron loaded mice to develop diabetes is
unclear. Of consideration for the Hepc1/ model is the age
and the genetic background of the mice. The study was per-
formed on 12-month-old mice on a mixed 129 and C57BL6 ge-
netic background. It will be interesting to determine whether
altered glucose homeostasis could be seen with aging and whenmice are backcrossed on the C57BL6 strain, which is known to
be a more diabetes-prone strain.
In conclusion, abnormal glucose tolerance and diabetes are
seen at signiﬁcant frequencies in humans with HH and the loss
of insulin secretory capacity is the primary event leading to
hemochromatosis related diabetes [13]. Our study, together
with the data of the literature, suggest that mice, for some
unknown reasons are resistant to the toxic eﬀects of iron-
induced organ damage and that diabetes is not a characteristic
of mouse models of HH. Consequently, these models are not
suitable to study the pathogenesis of diabetes associated with
hemochromatosis.
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